{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T11:39:21Z","timestamp":1791545961524,"version":"4.3.4"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2019,3,12]],"date-time":"2019-03-12T00:00:00Z","timestamp":1552348800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2019,6]]},"DOI":"10.1007\/s00415-019-09272-6","type":"journal-article","created":{"date-parts":[[2019,3,12]],"date-time":"2019-03-12T03:42:09Z","timestamp":1552362129000},"page":"1405-1411","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":44,"title":["Efficacy and safety of alemtuzumab in a real-life cohort of patients with multiple sclerosis"],"prefix":"10.1007","volume":"266","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9068-9144","authenticated-orcid":false,"given":"Jessica","family":"Frau","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giancarlo","family":"Coghe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorena","family":"Lorefice","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Fenu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luigina","family":"Musu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleonora","family":"Cocco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,3,12]]},"reference":[{"issue":"10130","key":"9272_CR1","doi-asserted-by":"publisher","first-page":"1622","DOI":"10.1016\/S0140-6736(18)30481-1","volume":"391","author":"AJ Thompson","year":"2018","unstructured":"Thompson AJ, Baranzini SE, Geurts J et al (2018) Multiple sclerosis. Lancet 391(10130):1622\u20131636","journal-title":"Lancet"},{"issue":"17","key":"9272_CR2","first-page":"1694","volume":"376","author":"X Montalban","year":"2017","unstructured":"Montalban X, Belachew S, Wolinsky JS (2017) Ocrelizumab in primary progressive and relapsing multiple sclerosis. N Engl J Med 376(17):1694","journal-title":"N Engl J Med"},{"issue":"17","key":"9272_CR3","doi-asserted-by":"publisher","first-page":"1786","DOI":"10.1056\/NEJMoa0802670","volume":"359","author":"AJ Coles","year":"2008","unstructured":"CAMMS223 Trial Investigators, Coles AJ, Compston DA, Selmaj KW et al. Alemtuzumab vs. interferon beta-1a in early multiple sclerosis. N Engl J Med. 2008;359(17):1786\u20131801","journal-title":"N Engl J Med"},{"issue":"9856","key":"9272_CR4","doi-asserted-by":"publisher","first-page":"1819","DOI":"10.1016\/S0140-6736(12)61769-3","volume":"380","author":"JA Cohen","year":"2012","unstructured":"Cohen JA, Coles AJ, Arnold DL et al (2012) Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial. Lancet 380(9856):1819\u20131828","journal-title":"Lancet"},{"issue":"9856","key":"9272_CR5","doi-asserted-by":"publisher","first-page":"1829","DOI":"10.1016\/S0140-6736(12)61768-1","volume":"380","author":"AJ Coles","year":"2012","unstructured":"Coles AJ, Twyman CL, Arnold DL et al (2012) Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial. Lancet 380(9856):1829\u20131839","journal-title":"Lancet"},{"issue":"11","key":"9272_CR6","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1212\/WNL.0000000000004313","volume":"89","author":"E Havrdova","year":"2017","unstructured":"Havrdova E, Arnold DL, Cohen JA et al (2017) Alemtuzumab CARE-MS I 5-year follow-up: durable efficacy in the absence of continuous MS therapy. Neurology 89(11):1107\u20131116","journal-title":"Neurology"},{"issue":"11","key":"9272_CR7","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1212\/WNL.0000000000004354","volume":"89","author":"AJ Coles","year":"2017","unstructured":"Coles AJ, Cohen JA, Fox EJ et al (2017) Alemtuzumab CARE-MS II 5-year follow-up: efficacy and safety findings. Neurology 89(11):1117\u20131126","journal-title":"Neurology"},{"issue":"9","key":"9272_CR8","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1007\/s11910-016-0685-y","volume":"16","author":"MD Willis","year":"2016","unstructured":"Willis MD, Robertson NP (2016) Alemtuzumab for multiple sclerosis. Curr Neurol Neurosci Rep 16(9):84","journal-title":"Curr Neurol Neurosci Rep"},{"issue":"21","key":"9272_CR9","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1212\/WNL.0000000000005561","volume":"90","author":"C Gerardi","year":"2018","unstructured":"Gerardi C, Bertele\u2019 V, Rossi S et al (2018) Preapproval and postapproval evidence on drugs for multiple sclerosis. Neurology 90(21):964\u2013973","journal-title":"Neurology"},{"issue":"10","key":"9272_CR10","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1177\/1756285617722706","volume":"10","author":"T Ziemssen","year":"2017","unstructured":"Ziemssen T, Thomas K (2017) Alemtuzumab in the long-term treatment of relapsing-remitting multiple sclerosis: an update on the clinical trial evidence and data from the real world. Ther Adv Neurol Disord 10(10):343\u2013359","journal-title":"Ther Adv Neurol Disord"},{"key":"9272_CR11","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.clineuro.2018.11.002","volume":"175","author":"GT Maniscalco","year":"2018","unstructured":"Maniscalco GT, Cerillo I, Servillo G et al (2018) Early neutropenia with thrombocytopenia following alemtuzumab treatment for multiple sclerosis: case report and review of literature. Clin Neurol Neurosurg 175:134\u2013136","journal-title":"Clin Neurol Neurosurg"},{"key":"9272_CR12","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.msard.2018.10.015","volume":"27","author":"BM Hoffman","year":"2019","unstructured":"Hoffman BM, Zeid NA, Alam U et al (2019) Lambert\u2013Eaton myasthenic syndrome associated with alemtuzumab administration. Mult Scler Relat Disord 27:131\u2013132","journal-title":"Mult Scler Relat Disord"},{"issue":"4","key":"9272_CR13","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1177\/1352458517699876","volume":"24","author":"U Ranganathan","year":"2018","unstructured":"Ranganathan U, Kaunzner U, Foster S et al (2018) Immediate transient thrombocytopenia at the time of alemtuzumab infusion in multiple sclerosis. Mult Scler 24(4):540\u2013542","journal-title":"Mult Scler"},{"key":"9272_CR14","first-page":"bcr-2018","volume":"2018","author":"J Madeley","year":"2018","unstructured":"Madeley J, Hodges G, Birchley A. Development of acquired haemophilia A in a patient treated with alemtuzumab for multiple sclerosis. BMJ Case Rep. 2018;2018: bcr-2018","journal-title":"BMJ Case Rep"},{"issue":"2","key":"9272_CR15","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/S1474-4422(16)30382-9","volume":"16","author":"A Haghikia","year":"2017","unstructured":"Haghikia A, Dendrou CA, Schneider R et al (2017) Severe B-cell-mediated CNS disease secondary to alemtuzumab therapy. Lancet Neurol 16(2):104\u2013106","journal-title":"Lancet Neurol"},{"issue":"7","key":"9272_CR16","doi-asserted-by":"publisher","first-page":"e601","DOI":"10.1212\/WNL.0000000000004950","volume":"90","author":"T Wehrum","year":"2018","unstructured":"Wehrum T, Beume LA, Stich O et al (2018) Activation of disease during therapy with alemtuzumab in 3 patients with multiple sclerosis. Neurology 90(7):e601\u2013e605","journal-title":"Neurology"},{"key":"9272_CR17","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/j.msard.2018.08.006","volume":"25","author":"R Bernard-Valnet","year":"2018","unstructured":"Bernard-Valnet R, Pignolet B, Biotti D et al (2018) Unexpected high multiple sclerosis activity after switching from fingolimod to alemtuzumab. Mult Scler Relat Disord 25:216\u2013218","journal-title":"Mult Scler Relat Disord"},{"issue":"2","key":"9272_CR18","doi-asserted-by":"publisher","first-page":"e320","DOI":"10.1212\/NXI.0000000000000320","volume":"4","author":"M Willis","year":"2017","unstructured":"Willis M, Pearson O, Illes Z et al (2017) An observational study of alemtuzumab following fingolimod for multiple sclerosis. Neurol Neuroimmunol Neuroinflamm 4(2):e320","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"2","key":"9272_CR19","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1136\/jnnp-2014-307721","volume":"86","author":"O Tuohy","year":"2015","unstructured":"Tuohy O, Costelloe L, Hill-Cawthorne G et al (2015) Alemtuzumab treatment of multiple sclerosis: long-term safety and efficacy. J Neurol Neurosurg Psychiatry 86(2):208\u2013215","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"12","key":"9272_CR20","doi-asserted-by":"publisher","first-page":"2851","DOI":"10.1007\/s00415-018-9070-x","volume":"265","author":"L Prosperini","year":"2018","unstructured":"Prosperini L, Annovazzi P, Boffa L et al (2018) No evidence of disease activity (NEDA-3) and disability improvement after alemtuzumab treatment for multiple sclerosis: a 36-month real-world study. J Neurol 265(12):2851\u20132860","journal-title":"J Neurol"},{"issue":"7","key":"9272_CR21","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.1007\/s00415-018-8871-2","volume":"265","author":"K Huhn","year":"2018","unstructured":"Huhn K, Bayas A, Doerck S et al (2018) Alemtuzumab as rescue therapy in a cohort of 50 relapsing-remitting MS patients with breakthrough disease on fingolimod: a multi-center observational study. J Neurol 265(7):1521\u20131527","journal-title":"J Neurol"},{"key":"9272_CR22","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.jns.2017.10.015","volume":"383","author":"NE Parks","year":"2017","unstructured":"Parks NE, Flanagan EP, Lucchinetti CF et al (2017) NEDA treatment target? No evident disease activity as an actionable outcome in practice. J Neurol Sci 383:31\u201334","journal-title":"J Neurol Sci"},{"issue":"6","key":"9272_CR23","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1177\/1352458516688350","volume":"23","author":"M Clerico","year":"2017","unstructured":"Clerico M, De Mercanti S, Artusi CA et al (2017) Active CMV infection in two patients with multiple sclerosis treated with alemtuzumab. Mult Scler 23(6):874\u2013876","journal-title":"Mult Scler"},{"issue":"7","key":"9272_CR24","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1001\/jamaneurol.2016.0826","volume":"73","author":"SE Hatcher","year":"2016","unstructured":"Hatcher SE, Waubant E, Nourbakhsh B et al (2016) Rebound syndrome in patients with multiple sclerosis after cessation of fingolimod treatment. JAMA Neurol 73(7):790\u2013794","journal-title":"JAMA Neurol"},{"issue":"10","key":"9272_CR25","doi-asserted-by":"publisher","first-page":"1270","DOI":"10.1111\/ene.13694","volume":"25","author":"J Frau","year":"2018","unstructured":"Frau J, Sormani MP, Signori A et al (2018) Clinical activity after fingolimod cessation: disease reactivation or rebound? Eur J Neurol 25(10):1270\u20131275","journal-title":"Eur J Neurol"},{"issue":"7","key":"9272_CR26","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1212\/WNL.0000000000004969","volume":"90","author":"H Wiendl","year":"2018","unstructured":"Wiendl H, Calabresi PA, Meuth SG (2018) Defining response profiles after alemtuzumab: rare paradoxical disease exacerbation. Neurology 90(7):309\u2013311","journal-title":"Neurology"},{"issue":"6","key":"9272_CR27","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1177\/1352458517694431","volume":"23","author":"M Sheikh-Taha","year":"2017","unstructured":"Sheikh-Taha M, Corman LC (2017) Pulmonary Nocardia beijingensis infection associated with the use of alemtuzumab in a patient with multiple sclerosis. Mult Scler 23(6):872\u2013874","journal-title":"Mult Scler"},{"issue":"1","key":"9272_CR28","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1007\/s00415-016-8306-x","volume":"264","author":"MR Blasco","year":"2017","unstructured":"Blasco MR, Ramos A, Malo CG et al (2017) Acute pneumonitis and pericarditis related to alemtuzumab therapy in relapsing-remitting multiple sclerosis. J Neurol 264(1):168\u2013169","journal-title":"J Neurol"},{"issue":"3","key":"9272_CR29","doi-asserted-by":"publisher","first-page":"e32487","DOI":"10.1371\/journal.pone.0032487","volume":"7","author":"C Sardu","year":"2012","unstructured":"Sardu C, Cocco E, Mereu A et al (2012) Population based study of 12 autoimmune diseases in Sardinia, Italy: prevalence and comorbidity. PLoS One 7(3):e32487","journal-title":"PLoS One"},{"issue":"11","key":"9272_CR30","doi-asserted-by":"publisher","first-page":"2494","DOI":"10.1007\/s00415-018-8822-y","volume":"265","author":"V Devonshire","year":"2018","unstructured":"Devonshire V, Phillips R, Wass H et al (2018) Monitoring and management of autoimmunity in multiple sclerosis patients treated with alemtuzumab: practical recommendations. J Neurol 265(11):2494\u20132505","journal-title":"J Neurol"},{"issue":"4","key":"9272_CR31","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/S1474-4422(17)30007-8","volume":"16","author":"T Kalincik","year":"2017","unstructured":"Kalincik T, Brown JWL, Robertson N et al (2017) Treatment effectiveness of alemtuzumab compared with natalizumab, fingolimod, and interferon beta in relapsing-remitting multiple sclerosis: a cohort study. Lancet Neurol 16(4):271\u2013281","journal-title":"Lancet Neurol"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-019-09272-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00415-019-09272-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-019-09272-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,3,10]],"date-time":"2020-03-10T20:06:56Z","timestamp":1583870816000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00415-019-09272-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3,12]]},"references-count":31,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2019,6]]}},"alternative-id":["9272"],"URL":"https:\/\/doi.org\/10.1007\/s00415-019-09272-6","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"value":"0340-5354","type":"print"},{"value":"1432-1459","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,3,12]]},"assertion":[{"value":"4 February 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 March 2019","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 March 2019","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 March 2019","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare no conflict of interests about this work.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}